Liquid biopsy in oncology practice: A global survey by the Young Committee of the International Society of Liquid Biopsy (ISLB).

Background: Liquid biopsy is a transformative tool for precision oncology, yet its clinical use remains variable across healthcare systems, and barriers to its implementation are poorly characterized. This survey aims to assess perceptions and practices related to liquid biopsy in oncology practice worldwide. Methods: A cross sectional, web-based survey was distributed to oncology providers worldwide from November 2024 to December 2025. The survey captured clinical practice characteristics, liquid biopsy uses and workflows, interpretation practices, reimbursement patterns, molecular tumor board (MTB) access, and perceived clinical- and system-level barriers. Descriptive statistics and subgroup comparisons were performed across geographic region, country income level, work setting, years in independent practice, and practice type. Results: Responses from 393 participants across 59 countries were analyzed, with 53% practicing in Europe. Most were medical oncologists (90%) self-identified as specialists (68%), practicing in academic centers (78%), and in high-income countries (70%). Liquid biopsy use was variable: 83% of respondents used it in ≤50% of patients, with pronounced differences across all subgroups (all Conclusions: These results highlight the high perceived value of liquid biopsy testing, while informing region- and setting-specific differences and challenges, which could be used to guide strategies to implement liquid biopsy in cancer care worldwide.